

# Lewis J Rubin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11324670/publications.pdf>

Version: 2024-02-01

254  
papers

48,712  
citations

3334

91  
h-index

1536

218  
g-index

265  
all docs

265  
docs citations

265  
times ranked

15456  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bosentan Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2002, 346, 896-903.	27.0	2,545
2	A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1996, 334, 296-301.	27.0	2,529
3	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157.	27.0	2,237
4	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1573-1619.	2.8	1,797
5	Inhaled Iloprost for Severe Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2002, 347, 322-329.	27.0	1,626
6	Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S5-S12.	2.8	1,542
7	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. <i>Lancet</i> , The, 2001, 358, 1119-1123.	13.7	1,421
8	Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1997, 336, 111-117.	27.0	1,294
9	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 800-804.	5.6	1,288
10	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 809-818.	27.0	1,168
11	Riociguat for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 330-340.	27.0	1,120
12	ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. <i>Circulation</i> , 2009, 119, 2250-2294.	1.6	992
13	Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 117, 3010-3019.	1.6	967
14	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 834-844.	27.0	906
15	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 425.	3.9	905
16	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 2243-2278.	2.2	903
17	Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2006, 113, 2011-2020.	1.6	791
18	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 2522-2533.	27.0	790

#	ARTICLE	IF	CITATIONS
19	Chronic Thromboembolic Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2001, 345, 1465-1472.	27.0	676
20	Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol). <i>Annals of Internal Medicine</i> , 1990, 112, 485.	3.9	621
21	Updated Treatment Algorithm of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D60-D72.	2.8	596
22	Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 1257-1263.	5.6	565
23	Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. <i>Annals of Internal Medicine</i> , 2008, 149, 521.	3.9	558
24	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134.	2.8	506
25	Primary pulmonary hypertension. <i>Lancet, The</i> , 1998, 352, 719-725.	13.7	505
26	Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2546-2552.	2.8	498
27	Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1915-1922.	2.8	484
28	Medical Therapy for Pulmonary Arterial Hypertension. <i>Chest</i> , 2007, 131, 1917-1928.	0.8	477
29	Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S78-S84.	2.8	463
30	Ambrisentan Therapy for Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2005, 46, 529-535.	2.8	441
31	Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 13861-13866.	7.1	395
32	Dysfunctional Voltage-Gated K <sup>+</sup> Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension. <i>Circulation</i> , 1998, 98, 1400-1406.	1.6	385
33	Preoperative Partitioning of Pulmonary Vascular Resistance Correlates With Early Outcome After Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2004, 109, 18-22.	1.6	377
34	The right ventricle in pulmonary hypertension. <i>Coronary Artery Disease</i> , 2005, 16, 13-18.	0.7	373
35	Primary Pulmonary Hypertension. <i>Chest</i> , 1993, 104, 236-250.	0.8	346
36	An overview of the 6th World Symposium on Pulmonary Hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802148.	6.7	345

#	ARTICLE	IF	CITATIONS
37	Upregulated <i>TRP</i> and enhanced capacitative $Ca^{2+}$ entry in human pulmonary artery myocytes during proliferation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H746-H755.	3.2	316
38	Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 624-633.	1.6	291
39	Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 247-254.	0.8	271
40	Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension. <i>Circulation</i> , 1997, 95, 1479-1486.	1.6	271
41	Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1527-1538.	2.8	269
42	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The Tj ETQq0 0 0 rgt/Overlook10 Tf 5	0.8	266
43	Attenuated $K^+$ channel gene transcription in primary pulmonary hypertension. <i>Lancet</i> , The, 1998, 351, 726-727.	13.7	263
44	Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. <i>Microvascular Research</i> , 2004, 68, 75-103.	2.5	263
45	Oral Hydralazine Therapy for Primary Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 1980, 302, 69-73.	27.0	256
46	Introduction. <i>Chest</i> , 2004, 126, 7S-10S.	0.8	244
47	Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 285, L740-L754.	2.9	237
48	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. <i>Chest</i> , 2011, 140, 1274-1283.	0.8	237
49	Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. <i>Chest</i> , 2004, 126, 420-427.	0.8	232
50	Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1272-1279.	5.6	227
51	Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1971-1981.	2.8	227
52	High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2003, 90, 372-376.	3.4	221
53	Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 293-299.	1.9	219
54	Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 194-201.	2.9	211

#	ARTICLE	IF	CITATIONS
55	CONTINUOUS INTRAVENOUS INFUSION OF EPOPROSTENOL FOR THE TREATMENT OF PORTOPULMONARY HYPERTENSION <sup>1</sup> . <i>Transplantation</i> , 1997, 63, 604-606.	1.0	208
56	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S81-S88.	2.8	206
57	Pathogenesis of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2005, 111, 534-538.	1.6	186
58	The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. <i>The American Review of Respiratory Disease</i> , 1989, 140, 1623-1630.	2.9	177
59	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). <i>European Respiratory Journal</i> , 2015, 45, 1303-1313.	6.7	174
60	Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?. <i>Chest</i> , 2006, 130, 1657-1663.	0.8	173
61	A Functional Single-Nucleotide Polymorphism in the <i>TRPC6</i> Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2009, 119, 2313-2322.	1.6	173
62	Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. <i>Chest</i> , 2009, 135, 122-129.	0.8	167
63	Chronic hypoxia decreases K <sub>V</sub> channel expression and function in pulmonary artery myocytes. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 280, L801-L812.	2.9	159
64	Endothelin receptor antagonists in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S62-S67.	2.8	153
65	Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. <i>Journal of Rheumatology</i> , 2007, 34, 2417-22.	2.0	152
66	Distinctive Clinical Features of Portopulmonary Hypertension. <i>Chest</i> , 1997, 112, 980-986.	0.8	149
67	Chronic thromboembolic pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2014, 2, 573-582.	10.7	146
68	Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. <i>American Journal of Physiology - Cell Physiology</i> , 2000, 279, C1540-C1549.	4.6	145
69	Clinical trial design and new therapies for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801908.	6.7	142
70	Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C1837-C1853.	4.6	141
71	Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 881-886.	5.6	141
72	Macitentan in pulmonary hypertension due to left ventricular dysfunction. <i>European Respiratory Journal</i> , 2018, 51, 1701886.	6.7	139

#	ARTICLE	IF	CITATIONS
73	Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology, 2006, 48, 1672-1681.	2.8	135
74	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.9	135
75	Capacitative Ca <sup>2+</sup> entry in agonist-induced pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L870-L880.	2.9	134
76	New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216.	5.6	129
77	Contemporary Trends in the Diagnosis and Management of Pulmonary Arterial Hypertension. Chest, 2013, 143, 324-332.	0.8	122
78	PORTOPULMONARY HYPERTENSION AND THE LIVER TRANSPLANT CANDIDATE. Transplantation, 1999, 67, 1087-1093.	1.0	122
79	Evaluation and Management of the Patient with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2005, 143, 282.	3.9	121
80	Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 48, 1433-1437.	2.8	115
81	SUCCESSFUL USE OF CHRONIC EPOPROSTENOL AS A BRIDGE TO LIVER TRANSPLANTATION IN SEVERE PORTOPULMONARY HYPERTENSION <sup>1</sup> . Transplantation, 1998, 65, 457-459.	1.0	115
82	New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. Journal of the American College of Cardiology, 2013, 62, D82-D91.	2.8	113
83	Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus. Chest, 2000, 117, 14-18.	0.8	109
84	Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. American Journal of Cardiology, 1981, 47, 116-122.	1.6	105
85	Molecular basis and function of voltage-gated K <sup>+</sup> channels in pulmonary arterial smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L621-L635.	2.9	103
86	CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 561-581.	2.1	102
87	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The Treprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation, 2011, 30, 1327-1333.	0.6	98
88	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	6.7	97
89	Prostacyclin and PGE1 Treatment of Pulmonary Hypertension. The American Review of Respiratory Disease, 1987, 136, 773-776.	2.9	96
90	Treatment of Primary Pulmonary Hypertension with Nifedipine. Annals of Internal Medicine, 1983, 99, 433.	3.9	92

#	ARTICLE	IF	CITATIONS
91	Primary Pulmonary Hypertension. <i>Medicine (United States)</i> , 1986, 65, 56.	1.0	91
92	Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1101-1107.	5.6	91
93	Pathology and pathophysiology of primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 1995, 75, 51A-54A.	1.6	85
94	ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. <i>Cardiovascular Therapeutics</i> , 2012, 30, 93-99.	2.5	85
95	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	2.8	82
96	Independence of Oxygen Consumption and Systemic Oxygen Transport in Patients with Either Stable Pulmonary Hypertension or Refractory Left Ventricular Failure <sup>1&amp;#x2013;4</sup> . <i>The American Review of Respiratory Disease</i> , 1983, 128, 30-33.	2.9	80
97	Pulmonary Arterial Hypertension. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 111-115.	3.5	80
98	Augmented K <sup>+</sup> currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L887-L894.	2.9	79
99	Upregulation of Na <sup>+</sup> /Ca <sup>2+</sup> exchanger contributes to the enhanced Ca <sup>2+</sup> entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C2297-C2305.	4.6	79
100	Temporal trends and drug exposures in pulmonary hypertension: An American experience. <i>American Heart Journal</i> , 2006, 152, 521-526.	2.7	78
101	Identification of putative endothelial progenitor cells (CD34 <sup>+</sup> CD133 <sup>+</sup> Flk-1 <sup>+</sup> ) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 296, L870-L878.	2.9	77
102	Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol. <i>Journal of Rheumatology</i> , 2009, 36, 2244-2249.	2.0	77
103	Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. <i>Life Sciences</i> , 2012, 91, 528-539.	4.3	76
104	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 37-47.	2.2	69
105	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 2440-2450.	1.6	67
106	Bosentan: a dual endothelin receptor antagonist. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 991-1002.	4.1	65
107	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155.	2.2	65
108	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 824-832.	2.6	64

#	ARTICLE	IF	CITATIONS
109	The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 249-252.	0.9	63
110	High sodium bicarbonate and acetate hemodialysis: Double-blind crossover comparison of hemodynamic and ventilatory effects. <i>Kidney International</i> , 1983, 24, 240-245.	5.2	62
111	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S108-S117.	2.8	62
112	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1286-1295.	0.6	62
113	The physiological basis of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2102334.	6.7	61
114	Executive Summary. <i>Chest</i> , 2004, 126, 4S-6S.	0.8	60
115	Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 391-405.	2.4	60
116	Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. <i>European Respiratory Review</i> , 2017, 26, 170094.	7.1	60
117	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 894-901.	10.7	59
118	Therapy of Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 1308-1309.	5.6	57
119	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 867-875.	6.7	56
120	Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. <i>Life Sciences</i> , 2012, 91, 517-521.	4.3	56
121	Influence of Prostaglandin Synthesis Inhibitors on Pulmonary Vasodilatory Effects of Hydralazine in Dogs with Hypoxic Pulmonary Vasoconstriction. <i>Journal of Clinical Investigation</i> , 1981, 67, 193-200.	8.2	55
122	A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. <i>American Heart Journal</i> , 1985, 110, 1200-1204.	2.7	52
123	Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8.	4.1	51
124	Mortality From Primary Pulmonary Hypertension in the United States, 1979-1996. <i>Chest</i> , 2000, 117, 796-800.	0.8	50
125	Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension. <i>Chest</i> , 2009, 135, 130-136.	0.8	49
126	Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 601-607.	3.5	48



#	ARTICLE	IF	CITATIONS
127	Primary Pulmonary Hypertension: An Unusual Case Associated with Extrahepatic Portal Hypertension. <i>Hepatology</i> , 1983, 3, 588-592.	7.3	48
128	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. <i>Chest</i> , 2016, 150, 27-34.	0.8	48
129	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. <i>International Journal of Cardiology</i> , 2014, 172, 332-339.	1.7	47
130	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 989-999.	2.9	47
131	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118.	0.8	46
132	c-Jun Decreases Voltage-Gated K <sup>+</sup> Channel Activity in Pulmonary Artery Smooth Muscle Cells. <i>Circulation</i> , 2001, 104, 1557-1563.	1.6	43
133	Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 124, 1612-1615.	0.8	43
134	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 50-56.	2.6	43
135	Inhaled treprostinil: a therapeutic review. <i>Drug Design, Development and Therapy</i> , 2012, 6, 19.	4.3	43
136	Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 9-19.	2.0	41
137	Update in Pulmonary Hypertension 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 499-505.	5.6	40
138	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , 2019, 21, 352-359.	7.1	40
139	Investigation and Management of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1414-1417.	2.9	39
140	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720.	6.7	39
141	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 300-309.	0.6	39
142	Gas exchange during dialysis. <i>American Journal of Medicine</i> , 1984, 77, 255-260.	1.5	38
143	Recreational Use of Aminorex and Pulmonary Hypertension. <i>Chest</i> , 2000, 118, 1496-1497.	0.8	38
144	Action of fenfluramine on voltage-gated K <sup>+</sup> channels in human pulmonary-artery smooth-muscle cells. <i>Lancet</i> , 1998, 352, 290.	13.7	37

#	ARTICLE	IF	CITATIONS
145	Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. <i>Journal of Rheumatology</i> , 2010, 37, 105-115.	2.0	37
146	Long-term Effects of Nitrendipine on Hemodynamics and Oxygen Transport in Patients with Cor Pulmonale. <i>Chest</i> , 1986, 89, 141-145.	0.8	36
147	Pulmonary arterial hypertension: a look to the future. <i>Journal of the American College of Cardiology</i> , 2004, 43, S89-S90.	2.8	34
148	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1360-1363.	0.9	34
149	Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2012, 110, 1546-1550.	1.6	34
150	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226.	2.5	33
151	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. <i>Current Therapeutic Research</i> , 2002, 63, 227-246.	1.2	32
152	Epoprostenol Therapy as a Bridge to Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2003, 123, 319-320.	0.8	32
153	Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. <i>Journal of Applied Physiology</i> , 1996, 81, 2595-2603.	2.5	31
154	Short-term Outcome and Predictors of Adverse Events following Pulmonary Thromboendarterectomy. <i>World Journal of Surgery</i> , 1998, 22, 1029-1033.	1.6	30
155	Effects of oral hydralazine on gas exchange in patients with cor pulmonale. <i>American Journal of Medicine</i> , 1983, 75, 937-942.	1.5	29
156	Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. <i>Cardiovascular Therapeutics</i> , 2013, 31, 38-44.	2.5	29
157	Prednisolone inhibits PDGF-induced nuclear translocation of NF- $\kappa$ B in human pulmonary artery smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 295, L648-L657.	2.9	28
158	ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , 2006, 130, 121S.	0.8	27
159	Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. <i>American Heart Journal</i> , 2014, 167, 218-225.e1.	2.7	27
160	Increased Levels of Prostaglandin D2 Suggest Macrophage Activation in Patients With Primary Pulmonary Hypertension. <i>Chest</i> , 2001, 120, 1639-1644.	0.8	26
161	Worldwide Physician Education and Training in Pulmonary Hypertension. <i>Chest</i> , 2010, 137, 85S-94S.	0.8	26
162	Relation between mixed venous oxygen tension and pulmonary vascular tone during normoxic, hyperoxic and hypoxic ventilation in dogs. <i>American Journal of Cardiology</i> , 1984, 54, 1118-1123.	1.6	25

#	ARTICLE	IF	CITATIONS
163	The 6-Minute Walk Test in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 396-397.	5.6	25
164	Treprostinil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 13-25.	1.5	25
165	Continuous Intravenous Epoprostenol Therapy for Pulmonary Hypertension in Gaucher's Disease. <i>Chest</i> , 1999, 116, 1127-1129.	0.8	23
166	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 689-697.	0.6	23
167	NEW AND EXPERIMENTAL THERAPIES FOR PULMONARY HYPERTENSION. <i>Clinics in Chest Medicine</i> , 2001, 22, 539-545.	2.1	22
168	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 509-519.	0.6	22
169	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <sc>GRIPHON</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 205-214.	7.1	22
170	Endothelin-1 and the Pulmonary Vascular Response to Altitude. <i>Circulation</i> , 2006, 114, 1350-1351.	1.6	21
171	Riociguat for Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 2266-2268.	27.0	21
172	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. <i>Chest</i> , 2021, 160, 277-286.	0.8	21
173	The Influence of the Transmembrane Sodium Gradient on the Responses of Pulmonary Arteries to Decreases in Oxygen Tension. <i>The American Review of Respiratory Disease</i> , 1989, 139, 933-939.	2.9	20
174	Exercise-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 118, 2120-2121.	1.6	20
175	Cardiovascular Effects of Vasodilator Therapy for Pulmonary Arterial Hypertension. <i>Clinics in Chest Medicine</i> , 1983, 4, 309-319.	2.1	20
176	Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1003-1011.	2.4	19
177	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 194-202.	0.6	19
178	Medical and Surgical Treatment Options for Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 1998, 315, 179-184.	1.1	19
179	Reversible pulmonary hypertension associated with anorexigen use. <i>American Journal of Medicine</i> , 1991, 91, 97-99.	1.5	18
180	lloprost inhalation solution for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1921-1930.	1.8	18

#	ARTICLE	IF	CITATIONS
181	Roles of K <sup>+</sup> and Cl <sup>-</sup> Channels in Camp-Induced Pulmonary Vasodilation. <i>Experimental Lung Research</i> , 1998, 24, 71-83.	1.2	17
182	Ambrisentan for pulmonary arterial hypertension. <i>Future Cardiology</i> , 2005, 1, 425-432.	1.2	17
183	Calcium Channel Blockers in Primary Pulmonary Hypertension. <i>Chest</i> , 1985, 88, 257S-260S.	0.8	16
184	Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. <i>Pediatric Pulmonology</i> , 1999, 27, 194-197.	2.0	16
185	The study of risk in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 234-238.	7.1	15
186	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI <sub>2</sub> ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 401-408.	0.6	15
187	Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1410-1417.	0.6	15
188	Noninvasive Evaluation of Right Ventricular Function. <i>Clinics in Chest Medicine</i> , 1987, 8, 65-80.	2.1	15
189	Approach to the Diagnosis and Treatment of Pulmonary Hypertension. <i>Chest</i> , 1989, 96, 659-664.	0.8	14
190	Indomethacin Prevents Ventilation-Induced Decreases in Pulmonary Vascular Resistance of the Middle Region in Fetal Lambs. <i>Pediatric Research</i> , 1991, 29, 449-454.	2.3	14
191	Chronic thromboembolic pulmonary hypertension. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 203-212.	3.1	14
192	Combination therapy for pulmonary hypertension: A glimpse into the future?. <i>Critical Care Medicine</i> , 2000, 28, 896-897.	0.9	13
193	Pulmonary Vascular Structural and Functional Changes in Papain-induced Emphysema in Dogs. <i>The American Review of Respiratory Disease</i> , 1987, 136, 704-709.	2.9	12
194	Performance of new criteria for right ventricular hypertrophy and myocardial infarction in patients with pulmonary hypertension due to cor pulmonale and mitral stenosis. <i>Journal of Electrocardiology</i> , 1991, 24, 231-237.	0.9	12
195	Cor Pulmonale Revisited. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1112-1113.	2.8	12
196	The Beta-Adrenergic Receptor in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 681-683.	2.8	12
197	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , 2022, 39, 796-810.	2.9	12
198	Primary pulmonary hypertension: new approaches to therapy. <i>American Heart Journal</i> , 1980, 100, 757-759.	2.7	10

#	ARTICLE	IF	CITATIONS
199	Central Venous Blood Oxygen Saturation Monitoring in Patients With Chronic Pulmonary Arterial Hypertension Treated With Continuous IV Epoprostenol. <i>Chest</i> , 2007, 132, 786-792.	0.8	10
200	Exercise training for pulmonary hypertension: another prescription to write?. <i>European Respiratory Journal</i> , 2012, 40, 7-8.	6.7	10
201	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 338-347.	0.6	10
202	Inhibition of K <sup>+</sup> Channel Activity in Human Pulmonary Artery Smooth Muscle Cells by Serum from Patients with Pulmonary Hypertension Secondary to Congenital Heart Disease. <i>Pediatric Research</i> , 2001, 50, 23-28.	2.3	9
203	Metabolic Dysfunction in the Pathogenesis of Pulmonary Hypertension. <i>Cell Metabolism</i> , 2010, 12, 313-314.	16.2	9
204	Effects of Interleukin-2 on Oxygen Delivery and Consumption in Patients with Advanced Malignancy. <i>Chest</i> , 1988, 94, 816-821.	0.8	8
205	Primary Pulmonary Hypertension. <i>Drugs</i> , 1992, 43, 37-43.	10.9	8
206	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011, 13, 114.	3.5	8
207	Cor Pulmonale Revisited. From Ferrer and Harvey to the Present. <i>Annals of the American Thoracic Society</i> , 2018, 15, S42-S44.	3.2	8
208	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005095.	2.2	8
209	Therapy of pulmonary hypertension: Targeting pathogenic mechanisms with selective treatment delivery. <i>Critical Care Medicine</i> , 2001, 29, 1086-1087.	0.9	8
210	Medical and Surgical Treatment Options for Pulmonary Hypertension. <i>American Journal of the Medical Sciences</i> , 1998, 315, 179-184.	1.1	7
211	Treatment of Pulmonary Arterial Hypertension Due to Scleroderma: Challenges for the Future. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 191-197.	1.9	7
212	<i>BMP2</i> Mutation and Outcome in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1300-1301.	5.6	7
213	Medical Treatment of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 484-492.	2.1	6
214	Treatment of Pulmonary Hypertension Caused by Left Heart Failure With Pulmonary Arterial Hypertension-Specific Therapies. <i>Circulation</i> , 2013, 128, 475-476.	1.6	6
215	Pulmonary Artery Denervation for Pulmonary Artery Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 2024-2025.	2.9	5
216	Improving patient outcomes in pulmonary hypertension. <i>European Respiratory Review</i> , 2015, 24, 550-551.	7.1	5

#	ARTICLE	IF	CITATIONS
217	Pulmonary Hypertension Overlap Syndromes. <i>Journal of the American College of Cardiology</i> , 2016, 68, 379-381.	2.8	5
218	Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era. <i>Circulation</i> , 2018, 137, 705-706.	1.6	5
219	Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011, 38, 2419-2427.	2.0	4
220	Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. <i>European Respiratory Journal</i> , 2015, 46, 297-298.	6.7	4
221	Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. <i>Vascular Pharmacology</i> , 2021, 138, 106840.	2.1	4
222	Effects of Nitrendipine and Hypoxia on Pulmonary Vascular Resistance in Experimental Emphysema. <i>The American Review of Respiratory Disease</i> , 1990, 142, 625-630.	2.9	3
223	Cardiovascular effects of pulmonary hypertension. <i>Trends in Cardiovascular Medicine</i> , 1991, 1, 65-69.	4.9	3
224	The Renin-Angiotensin System and the "Lesser Circulation". <i>Chest</i> , 1996, 110, 584-585.	0.8	3
225	Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. <i>Arthritis Research and Therapy</i> , 2007, 9, S10.	3.5	3
226	Combination Therapy for Pulmonary Artery Hypertension: What Is the Evidence?. <i>Cardiology</i> , 2011, 120, 172-173.	1.4	3
227	A paradigm shift in pulmonary arterial hypertension management. <i>European Respiratory Review</i> , 2013, 22, 423-426.	7.1	3
228	New horizons in pulmonary arterial hypertension management. <i>European Respiratory Review</i> , 2014, 23, 408-409.	7.1	3
229	Are Animal Models in Pulmonary Hypertension Relevant to the Clinical Disease? —. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2047-2049.	2.8	3
230	Therapy of Pulmonary Heart Disease. , 1984, , 325-353.		3
231	Nafazatrom (Bay G 6575) blunts canine hypoxic pulmonary vasoconstriction: Evidence for a prostaglandin-mediated mechanism. <i>Prostaglandins, Leukotrienes, and Medicine</i> , 1985, 18, 95-104.	0.7	2
232	Oxygen Therapy Titrated to Raise Mixed Venous Oxygen Content in COPD. <i>Chest</i> , 1986, 89, 343-347.	0.8	2
233	Management following pulmonary thromboendarterectomy: Experience versus evidence*. <i>Critical Care Medicine</i> , 2005, 33, 2132-2133.	0.9	2
234	Endothelin and the Systemic Circulation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1318-1319.	2.8	2

#	ARTICLE	IF	CITATIONS
235	Approach to pulmonary hypertension. <i>Current Rheumatology Reports</i> , 2000, 2, 517-523.	4.7	1
236	Bosentan. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 343.	2.2	1
237	Editor's response to "Ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 827-828.	0.6	1
238	Future Perspectives in Pulmonary Arterial Hypertension. <i>Progress in Respiratory Research</i> , 2012, , 276-279.	0.1	1
239	Overdue to understand anticoagulation in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-1.	1.7	1
240	Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. <i>Pediatric Pulmonology</i> , 1999, 27, 194-197.	2.0	1
241	Altered Expression and Function of Kv Channels in Primary Pulmonary Hypertension. , 2001, , 821-836.		1
242	Pulmonary Hypertension: Current Management and Future Directions. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 551-555.	1.8	1
243	Pulmonary Hypertension: Current Management and Future Directions. <i>Handbook of Experimental Pharmacology</i> , 2013, , 551-555.	1.8	1
244	Thyrotoxicosis as a Risk Factor for Pulmonary Arterial Hypertension. <i>Annals of Internal Medicine</i> , 2006, 144, 222.	3.9	1
245	The Sodium Gradient, Potassium Channels, and Regulation of Calcium in Pulmonary and Mesenteric Arterial Smooth Muscles: Effects of Hypoxia. , 1993, , 205-222.		1
246	It's Time to Put the Term "Pulmonary Vasodilators" to Rest. <i>JACC Basic To Translational Science</i> , 2021, 6, 870-871.	4.1	1
247	Effects of chronic anemic hypoxia on skeletal muscle mass, protein degradation, and oxygen utilization. <i>Journal of Critical Care</i> , 1990, 5, 10-19.	2.2	0
248	Different Vasoactive Mechanisms of Various Pulmonary Vasodilators-To the Editor. <i>Chest</i> , 1994, 105, 1920-1921.	0.8	0
249	IV Epoprostenol in Gaucher's Disease. <i>Chest</i> , 2000, 117, 1821.	0.8	0
250	Bosentan: profile report. <i>Drugs and Therapy Perspectives</i> , 2003, 19, 5-6.	0.6	0
251	Pulmonary Arterial Hypertension. , 2008, , 759-771.		0
252	Pulmonary Vasodilators in COPD. , 2009, , 699-704.		0

#	ARTICLE	IF	CITATIONS
253	Pulmonary Vasodilators. , 2002, , 605-609.		0
254	Clinical Evaluation. , 1984, , 107-115.		0